How does an investor profit if a company has the best technology in the world, but can't deliver market-beating returns? That's probably a harsh intro for Hologic (Nasdaq:HOLX) today, but the fact remains that the company has to demonstrate that it can drive tomosynthesis adoption and solid growth in diagnostics for this stock to really work over the coming years. That puts the shares in a challenging place for investors; bulls can likely see a lot of value here, while bears will point to the high debt and oncoming competition and likely conclude that the shares are best avoided for now.

Investopedia Broker Guide: Enhance your trading with the tools from today's top online brokers

A Decent Close to the Year
Due to an extra week in the quarter, a purchase accounting adjustment and the impact of the Gen-Probe acquisition, this was a messy quarter for Hologic investors. The good news is that, on balance, this a solid quarter with most of the key items ahead of expectations. Institutional and individual investors can effectively use earnings to gain a good hold on a company.

Revenue rose about 29%, including the purchase adjustment. On an organic basis, revenue rose about 7 to 8% (depending upon whether you factor in the extra week), with breast health revenue up about 6%, legacy diagnostics up 10% and gyn/surgery up 17% (ex-Adiana) on strong MyoSure performance. These results were all modestly better than expected, though it looks like Gen-Probe's growth was a little less impressive than previously forecast.

On the profit side, Hologic likewise did pretty well. Gross margin (adjusted) was up about a half-point from last year, but a little shy of most sell-side estimates. Operating income (also adjusted) rose about 28%, with a slightly better-than-expected operating margin.

Tomo Tomorrow?
Hologic continues to see customers its new(ish) tomosynthesis platform in the breast health business, but the pace continues to be slower than the original pre-launch hopes of most analysts. The issue is not that the system has disappointed clinicians or administrators, nor that General Electric (NYSE:GE), Siemens (NYSE:SI) or Philips (NYSE:PHG) are capturing share. Rather, the issue is that reimbursement has been slow to come and hospital administrators have to rational budget dollars across other options like Intuitive Surgical's (Nasdaq:ISRG) robots and Varian's (NYSE:VAR) radiation oncology systems, both of which have better-established reimbursement today.

In time, this situation should improve. The long-awaited Oslo dataset should be published next year, and that should open the door to better reimbursement. That said, the ongoing sluggishness and budget consciousness in Europe shouldn't be ignored, particularly as it may well shrink Hologic's time-to-market advantage over its rivals.

Navigating the Crosswinds in Diagnostics
Hologic's large diagnostics business is likewise facing some challenging crosswinds. On the negative side, the core ThinPrep business is being challenged by recommendations for larger intervals between tests. At the same time, companies like Cepheid (Nasdaq:CPHD), Qiagen (Nasdaq:QGEN) and Becton Dickinson (NYSE:BDX) are all trying to build their own diagnostics businesses and there are only so many dollars and patients to go around.

On the positive side, Cervista is growing well and HPV testing is still under-penetrated (and Qiagen should be a beatable opponent). Likewise, while core ThinPrep testing volume may be under pressure in the developed world, emerging market demand, while risky, should help offset this to some extent. Last and not least, Gen-Probe should improve Hologic's overall diagnostics platform, particularly enhancing efforts like molecular diagnostics and automated platforms.

The Bottom Line
Hologic had to use a lot more high-cost financing to do the Gen-Probe deal than originally hoped, and that carries a real cost. On the flip side, we're still talking about a business that has long generated good free cash flow, and that should add a deleveraging kicker to the Hologic bull thesis.

As I said in the intro, the fair value calculation on Hologic is a little more complicated than usual right now. Investors who believe that tomosynthesis adoption is a "when, not if" proposition and that Hologic will be the leading platform, as well as those who believe that Gen-Probe will strengthen Hologic's hand in diagnostics, will see these shares as offering pretty good long-term returns from these levels. I'm inclined to fly the flag for the bull camp when it comes to Hologic, but competition and leverage up the risks here and this is definitely not a stock for those looking for a conservative health care investment.

At the time of writing, Stephen D. Simpson did not own any shares in any company mentioned in this article.

Related Articles
  1. Stock Analysis

    3 Resilient Oil Stocks for a Down Market

    Stuck on oil? Take a look at these six stocks—three that present risk vs. three that offer some resiliency.
  2. Economics

    Keep an Eye on These Emerging Economies

    Emerging markets have been hammered lately, but these three countries (and their large and young populations) are worth monitoring.
  3. Stock Analysis

    Is Pepsi (PEP) Still a Safe Bet?

    PepsiCo has long been known as one of the most resilient stocks throughout the broader market. Is this still the case today?
  4. Investing

    The ABCs of Bond ETF Distributions

    How do bond exchange traded fund (ETF) distributions work? It’s a question I get a lot. First, let’s explain what we mean by distributions.
  5. Stock Analysis

    3 Stocks that Are Top Bets for Retirement

    These three stocks are resilient, fundamentally sound and also pay generous dividends.
  6. Investing News

    Are Stocks Cheap Now? Nope. And Here's Why

    Are stocks cheap right now? Be wary of those who are telling you what you want to hear. Here's why.
  7. Investing News

    4 Value Stocks Worth Your Immediate Attention

    Here are four stocks that offer good value and will likely outperform the majority of stocks throughout the broader market over the next several years.
  8. Investing News

    These 3 High-Quality Stocks Are Dividend Royalty

    Here are three resilient, dividend-paying companies that may mitigate some worry in an uncertain investing environment.
  9. Stock Analysis

    An Auto Stock Alternative to Ford and GM

    If you're not sure where Ford and General Motors are going, you might want to look at this auto investment option instead.
  10. Mutual Funds & ETFs

    The 4 Best Buy-and-Hold ETFs

    Explore detailed analyses of the top buy-and-hold exchange traded funds, and learn about their characteristics, statistics and suitability.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!